Back to search

Article

Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccines

2026-02-26

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> The SARS-CoV-2 LP.8.1 subvariant was incorporated into the 2025-2026 U.S. COVID-19 vaccines (mRNA-1273.251 and mRNA-1283.251). We evaluated immunogenicity and safety of these vaccines against vaccine-matched and emerging variants in individuals aged ≥65 and those aged 12-64 years at high-risk of severe COVID-19. <h4>Methods</h4> Data were generated from: (1) two independent...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7d5ac663-4900-5f6a-8b70-be7586ff74a8
DOI
10.64898/2026.02.24.26346954
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and safety of LP.8.1 variant-containing mRNA COVID-19 vaccinesDOI 10.64898/2026.02.24.26346954
Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort StudySemantic proximity
Comparison of Two Highly-Effective mRNA Vaccines for COVID-19 During Periods of Alpha and Delta Variant PrevalenceSemantic proximity
Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysisSemantic proximity
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalenceSemantic proximity
Depending on Epitope Profile of COVID-19 mRNA Vaccine Recipients: Are They More Efficient Against the Arising Viral Variants? An Opinion ArticleSemantic proximity
Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in FranceSemantic proximity
Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.SSemantic proximity
Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5Semantic proximity
Interim Safety and Immunogenicity of COVID-19 Omicron-BA.1 Variant-Containing Vaccine in ChildrenSemantic proximity
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesSemantic proximity
Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trialSemantic proximity
Select a neighboring publication to make it the new centre.